Drug intelligence / Profile preview

Audenkine

Development stage: Preclinical
Lead developer: Auxi Therapeutics
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
Administration: Intravenous

Overview

Audenkine is an autologous dendritic cell-cytokine-induced killer (DC-CIK) cell immunotherapy developed by Auxi Therapeutics. It is designed to treat various hematological malignancies (such as non-Hodgkin lymphoma, diffuse large B-cell lymphoma, multiple myeloma, Hodgkin lymphoma, and acute myeloid leukemia) and a wide range of solid tumors (including breast, lung, colorectal, gastric, pancreatic, and liver cancers, among others). The therapeutic mechanism of Audenkine combines dendritic-cell-mediated antigen presentation to stimulate a specific anti-tumor immune response with the direct, non-MHC-restricted cytotoxic activity of cytokine-induced killer cells against cancer cells.

Brand names: Audenkine

Targets

NKG2DL (NKG2D ligand family)CD28 (Cluster of Differentiation 28)γδ TCR (T-cell receptor)NKG2D (Natural killer group 2 member D receptor)pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on Audenkine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Audenkine.

Explore the full profile